Cited by 53Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

The Genetics of Very Early Onset Alzheimer Disease

Filley, Christopher M., Rollins, Yvonne D., Alan Anderson, C., Arciniegas, David B., Howard, Katherine L., Murrell, Jill R., Boyer, Philip J., Kleinschmidt-DeMasters, Belte K. +1 more·2007·Cognitive and Behavioral Neurology

Abstract

Objective This study was undertaken to clarify the genetics of very early onset Alzheimer disease (VEOAD), defined as AD beginning before age 35. Background Early onset AD (EOAD) is defined by onset of symptoms before age 65, and affected individuals may harbor a mutation in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein. VEOAD is exceedingly rare, and PSEN1 mutations have been implicated. We encountered a man with phenotypic frontotemporal dementia beginning at age 32 and a strong family history of an autosomal dominant dementia who was found at autopsy to have AD. Methods Histologic and genetic analyses of the patient's brain were undertaken, and a review of all published VEOAD cases was performed. Results Histologic findings were diagnostic of advanced stage AD. Genetic evaluation of brain tissue identified an intronic PSEN1 polymorphism; no known pathogenic mutation was found. Literature review (1934 to 2007) disclosed 101 cases of VEOAD; the youngest age of dementia onset was 24 years. In all cases in which definitive genetic analysis was available, either a PSEN1 mutation or linkage to chromosome 14 was found. Conclusions VEOAD can present with atypical clinical features, including findings suggestive of frontotemporal dementia. All reported cases of VEOAD with conclusive genetic analysis seem to be associated with PSEN1 mutations. Genetic testing in adults younger than 35 with dementia can identify the genetic defect and assist in diagnosis an…

Integrity signals

Registry

Crossref · 10.1097/wnn.0b013e318145a8c8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Autosomal-dominant AD is caused by mutations in APP and PSEN1 and PSEN2 genes.

    “Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [177]

  • Some PSEN1 mutations lead to very early onset ADAD (<35 years of age).

    “Some PSEN1 mutations lead to very early onset ADAD ( &lt; 35 yr of age) (177, 304).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [177]

Cited by

Sorted by citations

Authors
Filley, C. M., Rollins, Y. D., Alan Anderson, C., Arciniegas, D. B., Howard, K. L., Murrell, J. R., Boyer, P. J., Kleinschmidt-DeMasters, B. K., & Ghetti, B.
Affiliations
  • Denver VA Medical Center (US)
  • Neurology, Inc (US)
  • Indiana University Indianapolis (US)
Corresponding author
  • Filley, Christopher M.
  • Rollins, Yvonne D.
  • Arciniegas, David B.
  • Howard, Katherine L.
Venue
Cognitive and Behavioral Neurology
Published
2007-09
Volume
20
Issue
3
Pages
149-156
ISSN
1543-3633 (ISSN-L)
OpenAlex
W2047265153
Cited by
53
References
3
Citations by year
2026: 3 · 2023: 3 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 1
FWCI
3.75
Type
journal article
Language
en
Open access
closed
Locations
  • Cognitive and Behavioral Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (AG 10133, P30AG010133)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
presenilin 1, PSEN1 mutations, frontotemporal dementia, amyloid precursor protein, atypical presentation, genetic testing, family counseling
MeSH terms
Adult, Alzheimer Disease, Atrophy, Brain, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 21, Humans, Introns, Male, Neuropsychological Tests, Polymorphism, Genetic, Neurofibrillary Tangles, Point Mutation, Fatal Outcome, Presenilin-1, Presenilin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review